Efficacy News and Research

RSS

Viewpoints: Romney's surprisingly strong defense of Mass. health plan; Challenger's 'pretend' proposal for the nation

The first debate between President Obama and Mitt Romney, so long anticipated, quickly sunk into an unenlightening recitation of tired talking points and mendacity. With few sparks and little clarity on the immense gulf that truly separates the two men and their policies, Wednesday's encounter provided little guidance for voters still trying to understand the choice in next month's election.

5 Oct 2012

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting. The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way.

5 Oct 2012

Scripps Health receives Qualcomm Foundation grant to support digital medicine research projects

Scripps Health announced today that it has been awarded a $3.75 million grant from the Qualcomm Foundation, to be used for the Scripps Translational Science Institute, which was established by Scripps Health in collaboration with various parties to support the development of breakthrough digital technologies designed to revolutionize the practice of medicine.

4 Oct 2012

Krembil scientists develop lab study to accurately predict outcomes of stroke neuroprotectant

Scientists at the Krembil Neuroscience Centre, located at the Toronto Western Hospital, University Health Network have developed the first lab study in the world to accurately predict the outcomes of a human clinical for their drug that protects the brain against the damaging effects of stroke.

4 Oct 2012

Penn researchers to begin Microbion's BisEDT gel Phase 2 trials in post-surgical orthopedic infections

A team of researchers led by Samir Mehta, MD, chief of the Orthopaedic Trauma & Fracture Service at the Perelman School of Medicine at the University of Pennsylvania, has received a $2.5 million grant from the Congressionally Directed Medical Research Program (CDMRP), provided through the U.S. Department of Defense (DoD), to begin Phase 2 human trials of a study that examines the effective treatment of post-surgical orthopedic infections using Microbion Corporation's topical BisEDT drug.

4 Oct 2012

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.

4 Oct 2012

Tuberous sclerosis complex lesions respond well to everolimus in EXIST

Results from two phase III trials demonstrate significantly better skin lesion reduction with everolimus than placebo in patients with tuberous sclerosis complex.

3 Oct 2012

Routine screening influences outcomes in prostate cancer after surgery

Men who undergo radical prostatectomy for a tumor that was detected by screening show better long-term outcomes than their peers who undergo the surgery after opportunistic diagnosis, study results show.

3 Oct 2012

Beta-blockers do not appear to reduce risk of cardiovascular events in patients with CAD

Among patients with either coronary artery disease (CAD) risk factors only, known prior heart attack, or known CAD without heart attack, the use of beta-blockers was not associated with a lower risk of a composite of cardiovascular events that included cardiovascular death, nonfatal heart attack or nonfatal stroke, according to a study in the October 3 issue of JAMA.

3 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.

3 Oct 2012

Study investigates time-dependent efficacy of hUCB MNCs after experimental brain ischemia

A research team from Germany has found that optimal benefit and functional improvement for ischemic stroke results when human umbilical cord blood mononuclear cells (hUCB MNCs) are transplanted into rat stroke models within 72 hours of the stroke.

3 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

2 Oct 2012

Lighting the way to vascular lesion resolution

Treatment with a new-generation optimized pulsed light device significantly decreases the size and coloration of port wine stains and other vascular cutaneous lesions, show research findings.

2 Oct 2012

Adjuvants underused initially, follow up needed for cancer patients in pain

Italian study results indicate that physicians underuse adjuvant therapies for treatment of pain in cancer in the first instance, and that close follow up of oncology patients is needed to improve the efficacy of analgesic therapy in this setting.

2 Oct 2012

Multiple Epo doses with hypothermia offers neonate neuroprotection

Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.

1 Oct 2012

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

New insights on global fight to prevent cancers

New insights on the global fight to prevent cancers were presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. The studies highlight the challenges of overcoming misunderstandings about how important lifestyle factors are in reducing cancer risk.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Efficacy News and Research

Viewpoints: Romney's surprisingly strong defense of Mass. health plan; Challenger's 'pretend' proposal for the nation

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

Scripps Health receives Qualcomm Foundation grant to support digital medicine research projects

Krembil scientists develop lab study to accurately predict outcomes of stroke neuroprotectant

Penn researchers to begin Microbion's BisEDT gel Phase 2 trials in post-surgical orthopedic infections

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Tuberous sclerosis complex lesions respond well to everolimus in EXIST

Routine screening influences outcomes in prostate cancer after surgery

Beta-blockers do not appear to reduce risk of cardiovascular events in patients with CAD

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Study investigates time-dependent efficacy of hUCB MNCs after experimental brain ischemia

One rule for one and one for another with diabetes

Lighting the way to vascular lesion resolution

Adjuvants underused initially, follow up needed for cancer patients in pain

Multiple Epo doses with hypothermia offers neonate neuroprotection

EC approves Sosei’s Seebri Breezhaler to treat COPD

New insights on global fight to prevent cancers

Crizotinib effectively treats patients with ALK-positive lung cancer

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News